Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinicopathologic features of observed tumors in erlotinib-treated prevention cohort and controlsa

From: Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice

Clinicopathologic features Erlotinib (N= 13) Control (N= 14) Pvalue
Median disease-free survival, days 365 256 0.0001
Number of tumors 19 31 0.0003
ER-positive tumors 14 12 n.s.
ER-negative tumors 5 19 0.0000002
EGFRb    0.0004
   0 10 3  
   1+ 6 8  
   2+ 0 6  
   3+ 0 2  
Mean ALDH1b, % (±SD) 3.8% (2.8%) 9.0% (9.8%) 0.11 (n.s.)
Mean Ki-67b, % (±SD) 21.4% (14%) 30.4% (17.7%) 0.6 (n.s.)
Mean cleaved caspase 3b, % (±SD) 18.4% (8.6%) 10.6% (8.4%) 0.018
  1. aER, estrogen receptor; n.s., not significant; EGFR, epidermal growth factor receptor; ALDH1, aldehyde dehydrogenase 1; SD, standard deviation; bonly 16 tumors in the erlotinib-treated cohort and 19 tumors in the control cohort could be processed for EGFR, ALDH1, cleaved caspase 3 and Ki-67. A two-sided t-test was performed to analyze statistical significance.